Ayahuascafarmacología, efectos agudos, potencial terapéutico y rituales

  1. Aliño, Marta
  2. Gadea Doménech, Marien
  3. Pérez San Miguel, Joana
  4. Espert Tortajada, Raúl
Revista:
Revista española de drogodependencias

ISSN: 0213-7615

Ano de publicación: 2015

Número: 1

Páxinas: 75-91

Tipo: Artigo

Outras publicacións en: Revista española de drogodependencias

Resumo

Ayahuasca is a botanical hallucinogenic preparation which is made up of Banisteriopsis caapi and Psychotria viridis, consumed by indigenous groups of the Amazonia region. This beverage contains the serotoninergic agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine). Scientific literature has until now suggested that the administration or acute consumption of ayahuasca is not badly tolerated, even in situations where consumers have endured chronic use of the substance, no study having detected any effect of toxicological nature in humans. However, taking into account the limitations of performing most studies on a young and healthy sample, and the scant data on preexisting hepatic and cardiac pathologies, as well as the combined use of ayahuasca with other substances, a warning about the contraindication of ayahuasca use is suggested. The aim of this work is to put forward an overview through the composition and action mechanisms of ayahuasca and the desired and adverse effects of its administration. The use of this preparation as a new pharmacological therapy on substance abuse and affective disorders is explained, as well as a brief description regarding the connotations of ayahuasca use in organized rituals.

Referencias bibliográficas

  • Bouso, J.C., Fábregas, J.M., Antonijoan, R.M., Rodríguez-Fornells, A., Riba, J. (2013). Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology, 230(3),415-24. Doi:10.1007/s00213-013-3167-9
  • Bouso, J.C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P.C.R., Alcázar-Córcoles, M.Á., Araújo, W.S., Barbanoj, M.J., Fábregas, J.M., Riba, J. (2012). Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: A longitudinal study. PLoS ONE, 7(8), e42421.
  • Bouso, J.C., Riba, J. (2011). An overview of the literature on the pharmacology and neuropsychiatric long term effects of ayahuasca. En: R.G. dos Santos (Ed.) The Ethnopharmacology of Ayahuasca. Trivandrum: Transworld Research Network. Available at: http://www.trnres.com/ebook/ uploads/rafael/T_12998350823%20 Rafael.pdf
  • Brierley, D.I., Davidson, C. (2012). Deve- lopments in harmine pharmacology –Implications for ayahuasca use and drug-dependence treatment. Progress in Neuropsychopharmacology & Biological Psychiatry, 39(2), 263-272.
  • Brmham, C.R., Messaoudi, E. (2005). BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Progress in Neurobiolology, 76, 99-125.
  • Callaway, J.C.; Brito, G.S., Neves, E.S. (2005). Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis. Journal of Psychoactive Drugs, 37, 145-150.
  • Callaway, J.C., McKenna, D.J., Grob, C.S., Brito, G.S., Raymon, L.P., Poland, R.E. et ál. (1999). Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology, 65, 243-256.
  • Callaway, J.C., Airaksinen, M.M., McKenna, D.J., Brito, G.S., Grob, C.S. (1994). Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology (Berl.), 116(3): 385-7.
  • Carhart-Harris, R.L., Leech, R., Erritzoe, D., Williams, T., Stone, J.M., Evans, J. et ál. (2012). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophrenia Bulletin, 1-9 doi:10.1093/schbul/sbs117
  • Da Silveira, D.X., Grob, C.S., Dobkin de Rios, M., Lopez, E., Alonso, L.K. et ál. (2005). Ayahuasca in adolescence: A preliminary psychiatric assessment. Journal of Psychoactive Drugs, 37(2), 129-133.
  • De Almeida, J., Mengod, G. (2007). Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex. Journal of Neurochemistry, 103, 475-486.
  • De Araujo, D.B., Ribeiro, S., Cecchi, G.A., Carvalho, F.M., Sanchez, T.A., Pinto, J.P. et ál. (2012). Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Human Brain Mapping, 33(11), 2550-2560.
  • Dos Santos, R.G. (2013a). Safety and side effects of ayahuasca in humans –an overview focusing on developmental toxicology. Journal of Psychoactive Drugs, 45(1), 68-78.
  • Dos Santos, R.G. (2013b). A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. Journal of Psychoactive Drugs, 45(2), 179-188.
  • Dos Santos, R., Grasa, E., Valle, M., Ballester, M.R., Bouso, J.C., Nomdedéu, J.F. et ál. (2012). Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology, 219, 1039-1053.
  • Dos Santos, R.G.; Valle, M.; Bouso, J.C.; Nomdedéu, J.F.; Rodríguez-Espinosa, J.; McIlhenny, E.H. et ál. (2011). Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. Journal of Clinical Psychopharmacology, 31, 717-726.
  • Dos Santos, R.G. y Strassman, R.J. (2011). Ayahuasca and psychosis. En: R.G. dos Santos (Ed.). The Ethnopharmacology of Ayahuasca. Trivandrum: Transworld Research Network. Available in: http://www.trnres.com/ebook/uploads/rafael/T_12998353067%20 Rafael.pdf
  • Dos Santos, R.G. (2010). The pharmacology of ayahuasca: a review. Brasília Médica, 47(2), 188-195.
  • Doering-Silveira, E. Lopez, E., Grob, C.S., Dobkin de Rios, M., Alonso, L.K., Tacla, C. et ál. (2005). Ayahuasca in adolescence: A neuropsychological assessment. Journal of Psychoactive Drugs, 37(2), 123-128.
  • Fábregas, J.M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P.C. et ál. (2010). Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence, 111(3), 257-261.
  • Fortunato, J.J., Réus, G.Z., Kirsch, T.R., Stringari, R.B., Fries, G.R., Kapczinski, F. et ál. (2010). Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. Journal of Neural Transmission, 117(10), 1131-37.
  • Frankel, P.S., Cunningham, K.A. (2002). The hallucinogen d-lysergic acid diethylamide (dLSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Research, 958, 251-260.
  • Frecksa, E.; White, K.D. y Luna, L.E. (2004). Effects of ayahuasca on binocular rivality with dichotic stimulus alternation. Psychopharmacology (Berl.), 173, 79-87.
  • Frecksa, E., White, K.D., Luna, L.E. (2003). Effects of the Amazonian psychoactive beverage ayahuasca on binocular rivalry: Interhemispheric switching or interhemispheric fusión? Journal of Psychoactive Drugs, 35(3), 367-374.
  • Gouzouslis-Mayfrank, E., Habermeyer, E., Hermle, L., Steinmeyer, A., Kunert, H., Sass, H. (1998). Hallucinogenic drug-induced states resemble acute endogenous psychoses: results of an empirical study. European Psychiatry, 13, 399-406.
  • Grob, C.S., McKenna, D.J., Callaway, J.C., Brito, G.S., Neves, E.S., Oberlaender, G. et ál. (1996). Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. Journal of Nervous and Mental Disease, 184(2), 86-94.
  • Labate, B.C., Jungaberle, H. (2011). The Internationalization of Ayahuasca. Zurich: Lit Verlag.
  • Labate, B.C., MacRae, E. (2010). Ayahuasca, Ritual and Religion in Brazil. London: Equinox.
  • McKenna, D.J., Callaway, J.C., Grob, C.S. (1998). The scientific investigation of Ayahuasca: a review of past and current research. The Heffter Review of Psychedelic Research, 1, 65-77.
  • McKenna, D.C., Towers, G.H.N., Abbott, F. (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of Ayahuasca. Journal of Ethnopharmacology, 10: 195-223.
  • Osório, F.L., de Macedo, L.R.H., de Sousa, J.P.M., Pinto, J.P., Quevedo, J., Crippa, J.A.S. et ál. (2011). The therapeutic potential of harmine and ayahuasca in depression: evidence from exploratory animal and human studies. En: R.G. dos Santos (Ed.) The Ethnopharmacology of Ayahuasca, Trivandrum: Transworld Research Network. Available en: http://www.trnres.com/ebook/uploads/ rafael/T_12998352185%20Rafael.pdf
  • Owaisat, S., Raffa, R.B., Rawls, S.M. (2012). In vivo comparison of harmine efficacy against psychostimulants: Preferential inhibition of the cocaine response through a glutamatergic mechanism. Neuroscience Letters, 525(1): 12-06.
  • Palhano-Fontes, F., Alchieri, J.C., Oliveira, J.P.M., Soares, B.L., Hallak, J.E.C., Galvao-Coelho, N. et ál. (2014). The therapeutic potentials of ayahuasca in the treatment of depression. En: Clancy Cavnar (Ed.) The therapeutic use of ayahuasca, Heidelberg: Springer.
  • Prickett, J.I., Liester, M.B. (2014). Hypotheses regarding ayahuasca’s potential mechanisms of action in the treatment of addiction. En: Clancy Cavnar (Ed.) The therapeutic use of ayahuasca, Heidelberg: Springer.
  • Reichel-Dolmatoff, G. (1990). The cultural context of an aboriginal hallucinogen: Banisteriopsis caapi. En: Furst P (ed) Flesh Gods: the ritual use of hallucinogens. Waveland, Prospect Heights, IL, pp-84-113.
  • Réus, G.Z., Stringari, R.B., Gonçalves, C.L., Scaini, G., Carvalho-Silva, M., Jeremias, G.C. et ál. (2012). Administration of harmine and imipramine alters creatine kinase and mitocondrial respiratory chain activities in the rat brain. Depression Research and Treatment, 1-7.
  • Riba, J.; Romero, S.; Grasa, E.; Mena, E.; Carrió, I. y Barbanoj, M.J. (2006). Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant. Psychopharmacology, 186, 93-98.
  • Riba, J., Barbanoj, M.J. (2005). Bringing ayahuasca to the clinical research laboratory. Journal of Psychoactive Drugs, 37, 219-230.
  • Riba, J., Anderer, P., Jané, F., Saletu, B., Barbanoj, M.L. (2004). Effects of the South American psychoactive beverage Ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using lowresolution electromagnetic tomography. Neuropsychobiology, 50, 89-101.
  • Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., Barbanoj, M.J. (2003). Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306 (1), 73-83.
  • Riba, J. (2003). Human pharmacology of Ayahuasca. PhD. Thesis, Universitat Autònoma De Barcelona, Barcelona, Spain. Available at: http://tdx.cesca.es/TDX-0701104-165104/
  • Riba, J., Rodríguez-Fornells, A., Barbanoj, M.L. (2002). Effects of ayahuasca sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle réflex, respectively. Psychopharmacology, 165: 18-28.
  • Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M. et ál. (2001). Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology, 186(1), 85-95.
  • Samoylenko, V., Rahman, M.M., Tekwani, B.L., Tripathi, L.M., Wang, Y.H., Khan, S.I. et ál. (2010). Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. Journal of Ethnopharmacology, 127, 357-367.
  • Shanon, B. (2002). The Antipodes of the Mind: Charting the Phenomenology of the Ayahuasca Experience. New York: Oxford University Press.
  • Strassman, R.J.; Qualls, C.R. y Berg, L.M. (1996). Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biological Psychiatry, 39, 784-795.
  • Strassman, R.J. (1996). Human psychopharmacology of N,N-dimethyltryptamine. Behavioral Brain Research, 73, 121-124.
  • Viegas, D.R. y Berlanda, N. (2012). Ayahuasca, medicina del alma. Buenos Aires: Editorial Biblos.
  • Vollenweider, F.X. y Kometer, M. (2010). The neurobiology of psychodelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11, 642-651.